# Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

> **NCT02517866** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 380 (actual)

## Conditions studied

- Essential Hypertension
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Azilsartan Medoxomil

## Key facts

- **NCT ID:** NCT02517866
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-13
- **Primary completion:** 2016-11-15
- **Final completion:** 2016-11-25
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2019-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02517866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02517866, "Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02517866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*